Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003750 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00003750 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 28 participants.
The verdict
NCT00003750, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of hu14.18-interleukin-2 fusion protein in treating children who have refractory or recurrent neuroblastoma or other tumors.
Interventions
- BIOLOGICAL hu14.18-IL2 fusion protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2001-10 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003750
The ClinicalTrials.gov registry entry for NCT00003750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hu14.18-IL2 fusion protein is the first listed.
NCT00003750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003750 about?
NCT00003750 is a clinical study titled "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors". RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of hu14.18-interleukin-2 fusion protein in treating children who have refractory or re...
What is the current status of trial NCT00003750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2001-10. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00003750?
The interventions under investigation include: hu14.18-IL2 fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003750?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.